Filing Details
- Accession Number:
- 0000899243-22-010904
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-14 17:38:41
- Reporting Period:
- 2022-03-10
- Accepted Time:
- 2022-03-14 17:38:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1534120 | Avalo Therapeutics Inc. | AVTX | Pharmaceutical Preparations (2834) | 450705648 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1601086 | Armistice Capital, Llc | 510 Madison Avenue, 7Th Floor New York NY 10022 | Yes | No | Yes | No | |
| 1633584 | Ltd. Fund Master Capital Armistice | 510 Madison Avenue 7Th Floor New York NY 10022 | Yes | No | Yes | No | |
| 1706140 | Steven Boyd | 510 Madison Avenue 7Th Floor New York NY 10022 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-03-10 | 26,000 | $0.70 | 47,376,000 | No | 4 | P | Indirect | See Footnote |
| Common Stock | Acquisiton | 2022-03-11 | 100,000 | $0.69 | 47,476,000 | No | 4 | P | Indirect | See Footnote |
| Common Stock | Acquisiton | 2022-03-14 | 100,000 | $0.65 | 47,576,000 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See Footnote |
| No | 4 | P | Indirect | See Footnote |
| No | 4 | P | Indirect | See Footnote |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 412,442 | Direct |
Footnotes
- The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- These shares are directly owned by Mr. Boyd in his personal capacity.
Billionaire Hedge Funds
